LFCR Q2 2025 Earnings — Lifecore Biomedical, Inc. Revenue & Financial Results | Market Cap Arena

LFCRLifecore Biomedical, Inc.

$267M

Q2 2025 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$33M+8.0% YoY

Gross Profit

$11M34.0% margin

Operating Income

-$2M-6.0% margin

Net Income

-$7M-20.2% margin

EPS (Diluted)

$-0.25

QoQ Revenue Growth

+31.8%

Cash Flow

Operating Cash Flow

-$6M

Free Cash Flow

-$9M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$255M

Total Liabilities

$240M

Stockholders' Equity

$15M

Cash & Equivalents

$9M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$33M	$30M	+8.0%
Gross Profit	$11M	$10M	+11.3%
Operating Income	-$2M	-$1M	-32.1%
Net Income	-$7M	$14M	-146.2%